The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
Open accessAbstract
BACKGROUND: In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission. METHODS: Levels of BCR-ABL transcripts were measured by a quantitative real-time polymerase-chain-reaction assay. Results were expressed relative to the median level of BCR-ABL transcripts in the blood of 30 patients with untreated CML in chronic phase. RESULTS: In patients who had a complete cytogenetic remission, levels of BCR-ABL transcripts after 12 months of treatment had fallen by at least 3 log in 57 percent of those in the imatinib group and 24 percent of those in the group given interferon plus cytarabine (P=0.003). On the basis of the rates of complete cytogenetic remission of 68 percent in the imatinib group and 7 percent in the group given interferon plus cytarabine at 12 months, an estimated 39 percent of all patients treated with imatinib but only 2 percent of all those given interferon plus cytarabine had a reduction in BCR-ABL transcript levels of at least 3 log (P<0.001). For patients who had a complete cytogenetic remission and a reduction in transcript levels of at least 3 log at 12 months, the probability of remaining progression-free was 100 percent at 24 months, as compared with 95 percent for such patients with a reduction of less than 3 log and 85 percent for patients who were not in complete cytogenetic remission at 12 months (P<0.001). CONCLUSIONS: The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine. Patients in the imatinib group with this degree of molecular response had a negligible risk of disease progression during the subsequent 12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Goycoolea, A. (1997) · Cited by 3,615
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationDaley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L., & Ansari, H. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.850 · Cited by 819
Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370402 · Cited by 543
Cross, N. C. P., Feng, L., Chase, A., Bungey, J., Hughes, T., & Goldman, J. M. (1993) · Blood · doi:10.1182/blood.v82.6.1929.1929 · Cited by 365
Self-citationChronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders
Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P. C. A., Steegmann, J. L., et al. (2001) · Blood · doi:10.1182/blood.v98.10.3074 · Cited by 321
Self-citationChronic Myeloid Leukemia Trialists' Collaborative Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.21.1616 · Cited by 283
Emig, M., Saußele, S., Wittor, H., Weißer, A., Reiter, A., Willer, A., Berger, U., Hehlmann, R., Cross, N., & Hochhaus, A. (1999) · Leukemia · doi:10.1038/sj.leu.2401566 · Cited by 266
Self-citationHughes, T., Morgan, G. J., Martiat, P., & Goldman, J. M. (1991) · Blood · doi:10.1182/blood.v77.4.874.874 · Cited by 248
Self-citationBranford, Hughes, & Rudzki (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01749.x · Cited by 234
Chronic myeloid leukemia: current treatment options
Goldman, J. M., & Druker, B. J. (2001) · Blood · doi:10.1182/blood.v98.7.2039 · Cited by 224
Self-citationStaging and prognosis in chronic myelogenous leukemia.
Sokal, J. E., Baccarani, M., Russo, D., & Tura, S. (1988) · PubMed · Cited by 210
Hochhaus, A., Reiter, A., Reichert, S. S., Emig, M., Kaeda, J., Schultheis, B., Berger, U., Shepherd, P. C. A., Allan, N. C., Hehlmann, R., et al. (2000) · Blood · doi:10.1182/blood.v95.1.62 · Cited by 181
Self-citationLin, F., van Rhee, F., Goldman, J. M., & Cross, N. C. P. (1996) · Blood · doi:10.1182/blood.v87.10.4473.bloodjournal87104473 · Cited by 179
Self-citationHochhaus, A., Lin, F., Reiter, A., Skladny, H., Mason, P., van Rhee, F., Shepherd, P. C. A., Allan, N., Hehlmann, R., Goldman, J. M., et al. (1996) · Blood · doi:10.1182/blood.v87.4.1549.bloodjournal8741549 · Cited by 167
Self-citationBaccarani, M., Rosti, G., de Vivo, A., Bonifazi, F., Russo, D., Martinelli, G., Testoni, N., Amabile, M., Fiacchini, M., Montefusco, E., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1527 · Cited by 166
Olavarría, E., Kanfer, E., Szydlo, R., Kaeda, J., Rezvani, K., Cwynarski, K., Pocock, C., Dazzi, F., Craddock, C., Apperley, J. F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1560 · Cited by 157
Self-citationMahon, F., Delbrel, X., Cony-Makhoul, P., Fabères, C., Boiron, J.-M., Barthe, C., Bilhou‐Nabera, C., Pigneux, A., Marit, G., & Reiffers, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.214 · Cited by 152
Roth, M. S., Antin, J. H., Ash, R. C., Terry, V., Gotlieb, M., Silver, S., & Ginsburg, D. (1992) · Blood · doi:10.1182/blood.v79.1.276.276 · Cited by 146
Radich, J. P., Gooley, T., Bryant, E. M., Chauncey, T., Clift, R. A., Beppu, L. W., Edmands, S., Flowers, M. E. D., Kerkof, K., Nelson, R. B., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1701 · Cited by 143
Self-citationPreudhomme, C., Révillion-Carette, F., Merlat, A., Hornez, L., Roumier, C., Grardel, N., Jouet, J. P., Cosson, A., Peyrat, J., & Fenaux, P. (1999) · Leukemia · doi:10.1038/sj.leu.2401426 · Cited by 115
Miyamura, K., Tahara, T., Tanimoto, M., Morishita, Y., Kawashima, K., MORISHIMA, Y., Saito, H., Tsuzuki, S., Takeyama, K., & Kodera, Y. (1993) · Blood · doi:10.1182/blood.v81.4.1089.1089 · Cited by 109
Molecular monitoring of chronic myeloid leukemia
Hughes, T. P., & Branford, S. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70023-7 · Cited by 91
Self-citationWang, L., Pearson, K., Pillitteri, L., Ferguson, J. E., & Clark, R. E. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03705.x · Cited by 89
Mughal, T. I., Yong, A. S. M., Szydlo, R., Dazzi, F., Olavarría, E., van Rhee, F., Kaeda, J., Cross, N. C. P., Craddock, C., Kanfer, E., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03155.x · Cited by 70
Self-citationMorley, A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390911 · Cited by 28
Cited by
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationChemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citation
Metadata
- Authors
- Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., & Radich, J. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-10-09
- Volume
- 349
- Issue
- 15
- Pages
- 1423-1432
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079517811
- Cited by
- 1,218
- References
- 35
- FWCI
- 40.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.